top of page


Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection

GeneFirst has achieved another milestone this week with a clinical validation paper having been published under the VALidation of HPV GENotyping Tests (VALGENT) framework.

The Papilloplex high-risk human papillomavirus (hrHPV) test is a single tube real-time HPV test which provides multiplex detection and separate identification of 14 hrHPV types. The assay showed excellent agreement compared with GP5+/6+EIA Immunoassay using cervical specimens stored in SurePath medium, fulling the international clinical accuracy criteria for use in cervical cancer screening.

Click here to read to the full publication.

bottom of page